Arbutus Biopharma Corporation - Common Stock (ABUS)
3.3300
+0.0300 (0.91%)
Arbutus Biopharma Corp is a biotechnology company focused on developing innovative therapies for viral infections, particularly those caused by the hepatitis B virus (HBV)
The company is engaged in the discovery and development of a range of novel compounds aimed at addressing unmet medical needs in the treatment of chronic viral diseases. Arbutus employs a diverse approach to its research and development efforts, including the utilization of RNA interference technology and other mechanisms to advance its therapeutic candidates. Through its commitment to scientific excellence, Arbutus aims to provide effective treatment options that can significantly improve the lives of patients affected by viral infections.
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible future actions.
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSEPFE) and BioNTech SE NASDAQ: BNTXNASDAQBNTX)
Arbutus Biopharma (NASDAQABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
